Home/Filings/4/0000905148-26-000225
4//SEC Filing

Levy Adam D. 4

Accession 0000905148-26-000225

CIK 0001781174other

Filed

Jan 15, 7:00 PM ET

Accepted

Jan 16, 4:01 PM ET

Size

4.7 KB

Accession

0000905148-26-000225

Insider Transaction Report

Form 4
Period: 2026-01-14
Levy Adam D.
Chief Financial Officer
Transactions
  • Purchase

    Common Stock

    [F1]
    2026-01-14$1.70/sh+8,832$14,99920,983 total
Footnotes (1)
  • [F1]The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.695 to $1.7086, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4.
Signature
/s/ Adam D. Levy|2026-01-16

Documents

1 file

Issuer

Acrivon Therapeutics, Inc.

CIK 0001781174

Entity typeother

Related Parties

1
  • filerCIK 0002061876

Filing Metadata

Form type
4
Filed
Jan 15, 7:00 PM ET
Accepted
Jan 16, 4:01 PM ET
Size
4.7 KB